Drugs for Idiopathic Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 25)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
2 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
3 |
|
Antacids |
|
Phase 4 |
|
|
|
4 |
|
Anti-Ulcer Agents |
|
Phase 4 |
|
|
|
5 |
|
Serotonin Receptor Agonists |
|
Phase 4 |
|
|
|
6 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 4 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
Antemovis
|
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
Serotonine
sérotonine
thrombocytin
Thrombocytin
thrombotonin
Thrombotonin
|
|
7 |
|
Nortriptyline |
Approved |
Phase 3 |
|
72-69-5 |
4543 |
Synonyms:
(2)10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine
10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptene
10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine
10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-delta(5,g)-propylamine
10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine
10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-Delta(5,gamma)-propylamine
10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-δ(5,g)-propylamine
10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-δ(5,γ)-propylamine
10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Δ5,γ-propylamine
3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methylpropylamine
3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
3-(10,11-Dihydro-5H-dibenzo[a,D]cyclohepten-5-ylidene)-N-methyl-1-propanamine
5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene
5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
5-(alpha-Methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene
72-69-5
894-71-3
AB00052061
AC1L1IED
Acetexa
Allegron
Altilev
Apo nortriptyline
Apo-nortriptyline
Apotex brand OF nortriptyline hydrochloride
Ateben
Avantyl
Aventyl
AVENTYL HCL
BIDD:PXR0187
BPBio1_000076
BRD-K91263825-003-03-2
BRN 2216786
BSPBio_000068
BSPBio_002111
C07274
CAS-894-71-3
CCRIS 9175
CHEBI:7640
CHEMBL445
CID4543
D08288
DB00540
Demethylamitriptylene
Demethylamitriptyline
Demethylamitryptyline
Desitriptilina
Desitriptyline
Desmethylamitriptylin
Desmethylamitriptyline
Dista brand OF nortriptyline hydrochloride
DivK1c_000151
EINECS 200-788-8
Gen nortriptyline
Gen-nortriptyline
Genpharm brand OF nortriptyline hydrochloride
HMS1920B20
HMS2091J20
HMS500H13
Hydrochloride, nortriptyline
IDI1_000151
KBio1_000151
KBio2_001521
KBio2_004089
KBio2_006657
KBio3_001611
KBioGR_000870
KBioSS_001521
Lilly brand OF nortriptyline hydrochloride
Lopac0_000868
Lopac-N-7261
LS-60753
Lumbeck
Lundbeck brand OF nortriptyline hydrochloride
Mallinckrodt brand OF nortriptyline hydrochloride
MolPort-003-666-245
NCGC00014483
|
NCGC00014483-02
NCGC00014483-03
NCGC00014483-04
NCGC00014483-11
NCGC00024261-03
NCGC00024261-04
NCGC00024261-05
NCGC00024261-06
nchembio747-comp6
NCI169453
NCI60_001354
NCIOpen2_004361
NCIStruc1_000856
NCIStruc2_000700
NINDS_000151
N-Methyl-3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)propylamin
Noramitriptyline
Norfenazin
Noritren
Nortrilen
Nortrilen (TN)
Nortriptilina
Nortriptilina [DCIT]
Nortriptylene hydrochloride
Nortriptylina
nortriptyline
Nortriptyline
Nortriptyline (INN)
Nortriptyline [INN:BAN]
Nortriptyline Hcl
Nortriptyline hydrochloride
Nortriptylinum
Nortriptylinum [INN-Latin]
Nortryptiline
Nortryptyline
Norzepine
Novo nortriptyline
Novo-nortriptyline
Novopharm brand OF nortriptyline hydrochloride
NSC169453
NSC-169453
NSC78248
Nu nortriptyline
Nu pharm brand OF nortriptyline hydrochloride
Nu-nortriptyline
Nu-pharm brand OF nortriptyline hydrochloride
Pamelor
PAMELOR
Pamelor hydrochloride
Paxtibi
PDSP1_001805
PDSP2_001788
Pharmascience brand OF nortriptyline hydrochloride
PMS Nortriptyline
PMS-Nortriptyline
Prestwick0_000254
Prestwick1_000254
Prestwick2_000254
Prestwick3_000254
Psychostyl
QTL1_000063
Ratio nortriptyline
Ratio-nortriptyline
Ratiopharm brand OF nortriptyline hydrochloride
Reig jofre brand OF nortriptyline hydrochloride
Sensaval
Sensival Ventyl
Sesaval
SPBio_001093
SPBio_002287
Spectrum_001041
SPECTRUM1500442
Spectrum2_000997
Spectrum3_000526
Spectrum4_000455
Spectrum5_001377
UNII-BL03SY4LXB
Vividyl
|
|
8 |
|
Antidepressive Agents |
|
Phase 3 |
|
|
|
9 |
|
Antidepressive Agents, Tricyclic |
|
Phase 3 |
|
|
|
10 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
11 |
|
neurokinin A |
|
Phase 3 |
|
|
|
12 |
|
Substance P |
|
Phase 3 |
|
33507-63-0 |
44359816 |
Synonyms:
(2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulfanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidate
(2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulphanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidate
|
(2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulphanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidic acid
Arg-pro-lys-pro-GLN-GLN-phe-phe-gly-leu-met-NH2
|
|
13 |
|
Dopamine |
Approved |
Phase 2 |
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
Hydroxytyramin
|
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
14 |
|
Metoclopramide |
Approved, Investigational |
Phase 2 |
|
364-62-5 |
4168 |
Synonyms:
(metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide
(metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide
1,5-Dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one
2576-84-3 (di-hydrochloride)
2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide
2-Methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide
2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide
2-methoxy-5-chloroprocainamide
2-Methoxy-5-chloroprocainamide
364-62-5
4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide
4-Amino-5-chloro-2-methoxy-N-(b-diethylaminoethyl)benzamide
4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide
4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide
4-Amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide
4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide
4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-O-anisamide
4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp)
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide)
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide)
4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
54143-57-6 (mono-hydrochloride, mono-hydrate)
5-Chloro-2-methoxyprocainamide
7232-21-5 (mono-hydrochloride)
AB00053498
AC1L1HKD
AKOS000280832
Apo-Metoclop
ARONIS24307
Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy- (9CI)
Berk brand OF metoclopramide hydrochloride
Biomol-NT_000082
bmse000779
BPBio1_000217
BPBio1_001100
BRD-K75641298-001-01-5
BRD-K75641298-003-05-2
BRN 1884366
BSPBio_000197
BSPBio_002027
C07868
C14H22ClN3O2
CAS-7232-21-5
Cerucal
CHEBI:107736
CHEMBL86
CID4168
Clopra
CLOPRA-"YELLOW"
Clopra-Yellow
Clopromate
D00726
DB01233
DEL
DEL 1267
Dihydrochloride, metoclopramide
DivK1c_000069
Duraclamid
EINECS 206-662-9
Elieten
Elieten (TN)
Emetid
Emitasol
Emperal
Eucil
Gastrese
Gastrobid
Gastromax
Gastronerton
Gastrosil
Gastrotablinen
Gastrotem
Gastro-Timelets
HMS2089G16
Hydrochloride, metoclopramide
IDI1_000069
Imperan
KBio1_000069
KBio2_002118
KBio2_004686
|
KBio2_007254
KBio3_001527
KBioGR_001307
KBioSS_002118
L001078
Lopac0_000762
Lopac-M-0763
LS-20038
Maxeran
Maxolon
Meclopran
Metaclopramide
Metaclopromide
Metamide
Methochlopramide
Methoclopramide
Metochlopramide
Metoclol
Metoclopramida
Metoclopramida [INN-Spanish]
metoclopramide
Metoclopramide
Metoclopramide (JP15/INN)
Metoclopramide [INN:BAN:JAN]
Metoclopramide dihydrochloride
Metoclopramide Hcl
Metoclopramide hydrochloride
Metoclopramide Hydrochloride
Metoclopramide Intensol
Metoclopramide monohydrochloride
Metoclopramide monohydrochloride, monohydrate
Metoclopramide Monohydrochloride, Monohydrate
Metoclopramide Omega
Metoclopramidum
Metoclopramidum [INN-Latin]
Metocobil
Metramid
MolPort-000-883-854
Monohydrochloride, metoclopramide
Moriperan
Mygdalon
N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide
NCGC00015643-01
NCGC00015643-02
NCGC00015643-03
NCGC00015643-08
NCGC00024440-03
NCGC00024440-04
NCI60_003185
Neu-Sensamide
NINDS_000069
Nu-Metoclopramide
o-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)- (8CI)
Octamide
Parmid
Paspertin
Peraprin
Plasil
Plasil (pharmaceutical)
Pms-Metoclopramide
Pramidin
Pramiel
Pramin
Prestwick0_000209
Prestwick1_000209
Prestwick2_000209
Prestwick3_000209
Primperan
Reclomide
Reglan
Reliveran
Rimetin
SPBio_001740
SPBio_002118
Spectrum_001638
Spectrum2_001720
Spectrum3_000504
Spectrum4_000964
Spectrum5_001449
ST024773
Temmler brand OF metoclopramide hydrochloride
Terperan
Terperan (TN)
UNII-L4YEB44I46
|
|
15 |
|
Maleic acid |
Experimental |
Phase 2 |
|
110-16-7 |
444266 |
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-But-2-enedioate
(2Z)-But-2-enedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(Z)-Butenedioate
(Z)-Butenedioic acid
2-Butenedioate
2-Butenedioic acid
cis-1,2-Ethylenedicarboxylate
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
cis-Butenedioate
cis-Butenedioic acid
H2Male
Hydrogen maleate
|
Kyselina maleinova
MAE
Maleate
Maleic acid, ammonium salt
Maleic acid, calcium salt
Maleic acid, dipotassium salt
Maleic acid, disodium salt
Maleic acid, iron salt
Maleic acid, monoammonium salt
Maleic acid, monocopper (2+) salt
Maleic acid, monosodium salt
Maleic acid, neodymium salt
Maleic acid, potassium salt
Maleic acid, sodium salt
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Sodium maleate
Toxilate
Toxilic acid
|
|
16 |
|
Antiemetics |
|
Phase 2 |
|
|
|
17 |
|
Dopamine Agents |
|
Phase 2 |
|
|
|
18 |
|
Dopamine Antagonists |
|
Phase 2 |
|
|
|
19 |
|
Cola |
|
Phase 2 |
|
|
|
20 |
|
Pioglitazone |
Approved, Investigational |
Early Phase 1 |
|
111025-46-8 |
4829 |
Synonyms:
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione
(+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
105355-27-9
111025-46-8
198077-89-3
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione
5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
AB1004597
AC-1021
AC1L1J1Q
Actos
Actos (TN)
Actost
AD 4833
AD-4833
BRD-A48430263-003-02-4
BSPBio_002723
C07675
C19H20N2O3S
CHEBI:8228
CHEMBL595
CID4829
D08378
DB01132
Duetact
Glustin
HMS2089H14
HS-0047
HSDB 7322
|
I06-0089
KBio2_002103
KBio2_004671
KBio2_007239
KBio3_001943
KBioGR_001619
KBioSS_002103
LS-151327
MolPort-002-508-211
NCGC00163128-01
NCGC00163128-02
nchembio790-comp10
Pioglitazona
Pioglitazona [INN-Spanish]
Pioglitazone
pioglitazone (INN)
Pioglitazone [Ban:Inn]
Pioglitazone [BAN:INN]
Pioglitazone [INN:BAN]
pioglitazone HCl
Pioglitazone HCL
Pioglitazone hydrochloride
Pioglitazone Hydrochloride
Pioglitazonum
Pioglitazonum [INN-Latin]
Poglitazone hydrochloride
SPBio_001897
Spectrum_001623
Spectrum2_001679
Spectrum3_001002
Spectrum4_001130
Spectrum5_001480
Spectrum5_002067
U 72107
U 72107A
U72,107A
U-72107
UNII-X4OV71U42S
Zactos
|
|
21 |
|
Olanzapine |
Approved, Investigational |
|
|
132539-06-1 |
4585 135398745 |
Synonyms:
132539-06-1
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC1L1IHS
AC-665
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
Lanzac
Lilly brand of olanzapine
LS-152313
LY 170053
LY-170052
LY-170053
|
Midax
MLS000759457
MLS001165781
MLS001195646
MLS001424057
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
olanzapina
Olanzapina
olanzapine
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
Olanzapine pamoate
olanzapinum
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zolafren
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa intramuscular
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa zydis
Zyprexa Zydis
|
|
22 |
|
Hypoglycemic Agents |
|
Early Phase 1 |
|
|
|
23 |
|
Psychotropic Drugs |
|
|
|
|
|
24 |
|
Antipsychotic Agents |
|
|
|
|
|
25 |
|
Serotonin Uptake Inhibitors |
|
|
|
|
|
Interventional clinical trials:
(show all 15)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options |
Terminated |
NCT01281540 |
Phase 4 |
Cisapride;Placebo |
2 |
Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG) |
Completed |
NCT00765895 |
Phase 3 |
Nortriptyline Hydrochloride;Placebo (for nortriptyline) |
3 |
VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis |
Recruiting |
NCT04028492 |
Phase 3 |
Tradipitant;Placebo |
4 |
A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis |
Completed |
NCT03268941 |
Phase 2 |
TAK-906 Maleate;Metaclopramide;TAK-906 Maleate Placebo |
5 |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis |
Completed |
NCT02267525 |
Phase 2 |
Velusetrag;Placebo |
6 |
A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase 2 Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis |
Completed |
NCT01718938 |
Phase 2 |
velusetrag dose 1;velusetrag dose 2;velusetrag dose 3;placebo |
7 |
A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis |
Completed |
NCT03281577 |
Phase 2 |
TAK-954;Placebo |
8 |
Effects of Global Osteopathic Manual Treatments on Patients With Idiopathic Gastroparesis |
Unknown status |
NCT02232334 |
|
|
9 |
GpR 2: Continuation of the NIDDK Gastroparesis Registry for the Characterization and Clinical Course of Gastroparesis Patients |
Completed |
NCT01696747 |
|
|
10 |
Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients |
Completed |
NCT01916460 |
|
|
11 |
Study of the Antro-pyloro-duodenal Motor Dysfunction in Idiopathic Gastroparesis |
Completed |
NCT01519180 |
|
|
12 |
Endoscopic Full Thickness Biopsy of the Gastric Wall in Patients With Refractory Idiopathic Gastroparesis: Pilot Study to Detect Neuromuscular and Immune Pathologic Changes |
Completed |
NCT01650714 |
|
|
13 |
Pioglitazone for the Treatment of Idiopathic Gastroparesis (PIOGAS Study) |
Recruiting |
NCT04300127 |
Early Phase 1 |
Pioglitazone 30 mg |
14 |
A Pilot Study on the Efficacy and Safety of Olanzapine in Improving Symptoms and Gastric Motility in Gastroparesis |
Terminated |
NCT01625923 |
|
Olanzapine |
15 |
Idiopathic Gastroparesis Registry to Define Severity, Treatment Response, and Prognosis Using a Predominant-Symptom Classification |
Terminated |
NCT01173484 |
|
|
|